The FDA just approved a first-of-its-kind treatment for individuals with blood cancer that has proven results of 5-year survival rates. Christi Shaw, CEO of Kite, a Gilead company, joins Cheddar Innovates to discuss how this treatment works and compares to others currently on the market.
